AT 13148

Drug Profile

AT 13148

Alternative Names: AT-13148

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Astex Therapeutics; Cancer Research UK; The Institute of Cancer Research
  • Developer Astex Pharmaceuticals; Cancer Research UK
  • Class Antineoplastics; Benzamides; Piperidines; Small molecules
  • Mechanism of Action 70 kDa ribosomal protein S6 kinase inhibitors; Proto oncogene protein c-akt inhibitors; Rho-associated kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 23 May 2016 Phase-I development is ongoing in United Kingdom
  • 11 Oct 2013 Astex Pharmaceuticals has been acquired by Otsuka Pharmaceutical
  • 30 May 2012 Phase-I clinical trials in solid tumours in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top